Clostridia in cancer therapy

[1]  S. White,et al.  Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. , 2003, Cancer research.

[2]  Ernst Wagner,et al.  Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[3]  L. Naldini,et al.  In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. , 2003, Human gene therapy.

[4]  J. A. George,et al.  Gene therapy progress and prospects: adenoviral vectors , 2003, Gene Therapy.

[5]  M. Ogris,et al.  Tissue-dependent factors affect gene delivery to tumors in vivo , 2003, Gene Therapy.

[6]  S. Okabe,et al.  Adenovirus-mediated prodrug-enzyme therapy for CEA-producing colorectal cancer cells , 2003, Journal of Cancer Research and Clinical Oncology.

[7]  J. Brueggen,et al.  A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs , 2003, British Journal of Cancer.

[8]  H. Spearman,et al.  Hypoxia-mediated tumour targeting , 2003, Gene Therapy.

[9]  J. B. Connolly,et al.  Conditionally replicating viruses in cancer therapy , 2003, Gene Therapy.

[10]  M. Dobbelstein.  Viruses in therapy--royal road or dead end? , 2003, Virus research.

[11]  D. Kerr,et al.  Immune enhancement of nitroreductase‐induced cytotoxicity: Studies using a bicistronic adenovirus vector , 2003, International journal of cancer.

[12]  Gengfeng Fu,et al.  Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective inhibitor of angiogenesis and hypoxic tumor growth , 2003, Cancer Gene Therapy.

[13]  P. Wils,et al.  Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors , 2002, Gene Therapy.

[14]  A. Patterson,et al.  Novel chimeric gene promoters responsive to hypoxia and ionizing radiation , 2002, Gene Therapy.

[15]  C. Springer,et al.  A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours , 2002, British Journal of Cancer.

[16]  S. Taniguchi,et al.  The genus Bifidobacterium for cancer gene therapy. , 2002, Current opinion in drug discovery & development.

[17]  A. Rees,et al.  A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics , 2002, Proteomics.

[18]  S. Hay,et al.  Satellite imagery in the study and forecast of malaria , 2002, Nature.

[19]  AJ Giaccia,et al.  Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis , 2002, Gene Therapy.

[20]  O. Bjørnstad,et al.  Travelling waves and spatial hierarchies in measles epidemics , 2001, Nature.

[21]  K. Kinzler,et al.  Combination bacteriolytic therapy for the treatment of experimental tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. McLeod,et al.  Strategies for enzyme/prodrug cancer therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  P. Lambin,et al.  Insertion or Deletion of the Cheo Box Modifies Radiation Inducibility of Clostridium Promoters , 2001, Applied and Environmental Microbiology.

[24]  J. Nemunaitis,et al.  A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. , 2001, Human gene therapy.

[25]  P. Lambin,et al.  Radio-responsive recA promoter significantly increases TNFα production in recombinant clostridia after 2 Gy irradiation , 2001, Gene Therapy.

[26]  P. Lambin,et al.  The Use of Radiation-Induced Bacterial Promoters in Anaerobic Conditions: A Means to Control Gene Expression in Clostridium-Mediated Therapy for Cancer , 2001, Radiation research.

[27]  P. Lambin,et al.  Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum , 2001, Cancer Gene Therapy.

[28]  X. Luo,et al.  Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. , 2001, Oncology research.

[29]  Hubert Bahl,et al.  Clostridia-Biotechnology and Medical Applications , 2001 .

[30]  P. Lambin,et al.  Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. , 2001, FEMS immunology and medical microbiology.

[31]  D. Curiel,et al.  Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. , 2000, Cancer research.

[32]  D. Rogers,et al.  Fragile transmission cycles of tick-borne encephalitis virus may be disrupted by predicted climate change , 2000, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[33]  C. Balagué,et al.  Replicative adenoviruses for cancer therapy , 2000, Nature Biotechnology.

[34]  Y. Kano,et al.  Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors , 2000, Cancer Gene Therapy.

[35]  P. Lambin,et al.  Stable Escherichia coli-Clostridium acetobutylicum Shuttle Vector for Secretion of Murine Tumor Necrosis Factor Alpha , 1999, Applied and Environmental Microbiology.

[36]  G. Semenza.  Hypoxia-inducible factor 1: master regulator of O2 homeostasis. , 1998, Current opinion in genetics & development.

[37]  P. Lambin,et al.  Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. , 1998, Anaerobe.

[38]  J. Pawelek,et al.  Tumor-targeted Salmonella as a novel anticancer vector. , 1997, Cancer research.

[39]  P. V. Zijl,et al.  Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment , 1997, Gene Therapy.

[40]  A. Giaccia,et al.  Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. , 1996, Gene therapy.

[41]  A. Giaccia,et al.  Chemotherapeutic tumour targeting using clostridial spores. , 1995, FEMS microbiology reviews.

[42]  F. Friedlos,et al.  The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). , 1992, Biochemical pharmacology.

[43]  K. D. Bagshawe,et al.  Antibody directed enzymes revive anti-cancer prodrugs concept. , 1987, British Journal of Cancer.

[44]  R. A. Malmgren,et al.  Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. , 1955, Cancer research.

[45]  R. C. Parker,et al.  Effect of Histolyticus Infection and Toxin on Transplantable Mouse Tumors.∗ , 1947, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[46]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[47]  John Mao,et al.  Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  N. Minton,et al.  Bacillus amyloliquefaciens orthologue of Bacillus subtilis ywrO encodes a nitroreductase enzyme which activates the prodrug CB 1954. , 2002, Microbiology.

[49]  P. Lambin,et al.  Clostridium as a tumor-specific delivery system of therapeutic proteins. , 2001, Cancer detection and prevention.

[50]  R. Maxwell,et al.  Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. , 2000, Advances in experimental medicine and biology.

[51]  S. Hay.  An overview of remote sensing and geodesy for epidemiology and public health application. , 2000, Advances in parasitology.

[52]  R. Maxwell,et al.  Combretastatins Novel Vascular targeting Drugs for Improving Anticancer therapy , 2000 .

[53]  Samuel I. Miller,et al.  Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo , 1999, Nature Biotechnology.

[54]  Arnold L. Demain,et al.  Manual of Industrial Microbiology and Biotechnology , 1986 .

[55]  A. Polak,et al.  Metabolic studies with 5-fluorocytosine-6-14C in mouse, rat, rabbit, dog and man. , 1976, Chemotherapy.